KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Short term Debt (2019 - 2025)

Historic Short term Debt for Royalty Pharma (RPRX) over the last 7 years, with Q3 2025 value amounting to $380.0 million.

  • Royalty Pharma's Short term Debt fell 6188.34% to $380.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $380.0 million, marking a year-over-year decrease of 6188.34%. This contributed to the annual value of $997.8 million for FY2024, which is N/A changed from last year.
  • According to the latest figures from Q3 2025, Royalty Pharma's Short term Debt is $380.0 million, which was down 6188.34% from $999.4 million recorded in Q2 2025.
  • Over the past 5 years, Royalty Pharma's Short term Debt peaked at $999.4 million during Q2 2025, and registered a low of $107.9 million during Q4 2021.
  • Moreover, its 5-year median value for Short term Debt was $996.6 million (2022), whereas its average is $603.3 million.
  • Per our database at Business Quant, Royalty Pharma's Short term Debt soared by 82418.7% in 2022 and then crashed by 6188.34% in 2025.
  • Over the past 5 years, Royalty Pharma's Short term Debt (Quarter) stood at $107.9 million in 2021, then surged by 824.19% to $997.5 million in 2022, then increased by 0.19% to $999.4 million in 2023, then decreased by 0.16% to $997.8 million in 2024, then crashed by 61.92% to $380.0 million in 2025.
  • Its Short term Debt was $380.0 million in Q3 2025, compared to $999.4 million in Q2 2025 and $998.6 million in Q1 2025.